That point was driven home today by the regulatory approval of Eloxatin, or oxaliplatin, a treatment for colorectal cancer developed by Sanofi-Synthelabo .
For example, Bristol-Myers and ImClone are now in trials combining Erbitux with yet another colon cancer chemo drug, oxaliplatin from Sanofi-Synthelabo (nyse: SNY - news - people ).